SecBot SecBot
Insider Cluster (4 insiders) ·Filed Aug 17, 2026

RCKT

ROCKET PHARMACEUTICALS, INC.
NEUTRAL
Impact 4/10
Horizonweeks Processed3mo ago
Insider cluster: 3 insiders, $0.2M total
Actionable Insight • Neutral

The insider sales are small relative to market cap and likely routine profit-taking or liquidity-driven, especially given the positive earnings catalyst. However, the cluster includes the CEO and COO selling immediately after a PRV-driven earnings beat, monitor for any additional insider sales in the next 30 days; a continuation would increase bearish signal. The stock's 55% analyst bullish consensus and $283.7M cash runway provide a fundamental floor, but the lack of insider buying at these depressed levels is a subtle negative.

DirectionNeutral
Confidencemedium
Horizonweeks

RP-A501

● Neutral Named in this insider cluster
Impact
Phase
Phase 2 (pivotal/registrational)
Time to market
If the pivotal Phase 2 trial succeeds, a BLA submission for accelerated approval could follow in 2028-2029, given the 12-month endpoint timeline with last patient dosed by mid-2027.
Next catalyst
None dated

What to watchWatch for updates on enrollment of the remaining 9 patients in the pivotal Phase 2 trial and any interim data presentations at medical conferences in 2027. The FDA alignment in September 2026 de-risked the regulatory path, but the stock near its 52-week low reflects lingering safety concerns and a long wait until topline data (likely 2028). KRESLADI commercial traction is a separate value driver that could support the stock in the interim.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.34
T+0 close · Aug 17, 2026 · via day close
Latest settled
−26.65%
T+60 · $2.45
Vs SPY
−24.61%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 18 $3.34entry
  2. T+1 · 3mo ago +9.28%α +9.07% · $3.65
  3. T+5 · 3mo ago +13.17%α +13.37% · $3.78
  4. T+20 · 2mo ago +4.49%α +5.48% · $3.49
  5. T+60 · 6d ago −26.65%α −24.61% · $2.45

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Three Rocket Pharmaceuticals insiders, including the CEO and COO, sold a total of $154K in open-market sales over a 7-day window following the company's Q2 2026 earnings release. The earnings report showed a GAAP net income of $123.2M driven by a $178.2M PRV sale, but the insider selling cluster, particularly the COO's $128K sale, suggests insiders are taking profits or lack conviction in the stock's near-term upside at the current ~$3.50 price level. The total dollar value is 0.04% of the $381M market cap, which is trivial and likely routine, but the cluster's proximity to positive earnings and the CEO's participation warrants attention.

Key Financial Metrics

Direction
selling
Total Value
$154.0K
Insiders
4

Key Facts

  • CEO Shah Gaurav sold 2,837 shares at $3.381 for ~$10K on 2026-08-13.
  • COO Stevens Christopher James sold 36,658 shares at $3.499 for ~$128K on 2026-08-11.
  • General Counsel Wilson Martin sold 3,493 shares at $3.381 for ~$12K on 2026-08-13.
  • Total insider sales of $154K represent 0.04% of RCKT's $381M market cap, trivial by proportionality standards.
  • Sales occurred 3-7 days after Q2 2026 earnings showing a $123.2M GAAP net income, driven by a $178.2M PRV sale.
  • The company ended Q2 2026 with $283.7M cash, extending runway into Q2 2028.

Financial Impact

Total insider sales of $154K, or 0.04% of market cap, are immaterial to the company's financial position.

dilution

Risk Factors

  • Insider selling cluster may signal lack of confidence in near-term stock appreciation despite positive earnings.
  • The $178.2M PRV gain is non-recurring; core operating loss of $46.9M in Q2 2026 still indicates cash burn.
  • Stock price at ~$3.50 is near 52-week lows; further insider sales could exacerbate selling pressure.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
55% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-RCKT-1787004115933

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 17, 2026